| Objective:To investigate the expression of CD163 and CD204 in human serous ovarian tumor tissues and pericancerous, and Arg-1 in serum of patients, and the relationship between their expression with the development of serous ovarian cancer, and to detect their clinicopathological significances. Methods:Arg-1 was measured by immunoassay in serum of 41 women with ovarian carcinoma,22 women with benign gynecological conditions and 15 ovarian healthy women.And Immunohi-stochemistry(DAB method)was used to detect expression of CD 163 and CD204 in human serous ovarian cancer and pericancerous tissues,and to detect their relationship between the clinicopathological factors.Results:①The concentration of Arg-1 in serum of serous ovarian cancer patients is significantly higher than those of benign disease patients and normal(P<0.05),what is accordant with the expression of M2-TAM in human serous cancer tissues.②The positive rate of CD 163 in the benign gynecological conditions were22.7%,and in ovarian healthy wamen were 13.3%, in serous ovarian cancer tissues were 60.1%, three groups were significantly different in statistical way(P=0.009).③he positive rate of CD204 in the benign gynecological conditions were31.8%,and in ovarian healthy wamen were6.7%,in serous ovarian cancer tissues were 68.3%(28/41). three groups were significantly different in statistical way (P=0.026).④The positive rate of CD163 and CD204 in serous ovarian cancer tissues were 60.1%,68.3%,while in the pericancerous tissues were 30.0%,35.0%. the expression of CD163 and CD204 in serous ovarian cancer and the pericancerous tissues were significantly different in statistical way(P<0.05).⑤The positive rate of CD 163 and CD204 in serous ovarian cancer tissues have relationship with clinical statespathological gradient,without or with-metastasis of lymphnodes(P<0.05).Conclusions:M2-tumor associated macrophage(M2-TAM)considered to promote tumor growth and metastasis.,and Arg-1 is a new biomarker for serous ovarian cancer. |
PDF Full Text Request